Exchange: NASDAQ·Updated 01:37 PM EDT
BCAB logo

BCAB BioAtla Inc

$1.79
$0.11
(5.79%)
Today
EarningsNov 12
Mkt Cap$2.98M
Vol2,868.00

About BCAB

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
62

Bullish Sentiment

How do you feel about BCAB?

Advertisement|Remove ads.